• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

依托珠单抗治疗银屑病。

Itolizumab in Psoriasis.

作者信息

Srivastava Ankita

机构信息

Department of Skin and VD, JNU Institute for Medical Sciences and Research Centre, Jaipur, Rajasthan, India.

出版信息

Indian J Dermatol. 2017 Jul-Aug;62(4):418-421. doi: 10.4103/ijd.IJD_467_16.

DOI:10.4103/ijd.IJD_467_16
PMID:28794555
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5527725/
Abstract

A number of biologics is being used for the treatment of psoriasis. Itolizumab is one such agent which has been approved in India. It is an anti-CD6 monoclonal antibody that acts by binding to scavenger receptor cysteine-rich (SRCR) distal domain 1 of CD6. Itolizumab has been found to be safe, with infusion reactions as the most common adverse effect. However, its advantages and disadvantages over other biologicals and immunosuppressants need to be established. Also, its utility in treating other immune-mediated disorders is being explored.

摘要

许多生物制剂正被用于治疗银屑病。依妥珠单抗就是其中一种已在印度获批的药物。它是一种抗CD6单克隆抗体，通过与CD6的富含半胱氨酸的清道夫受体（SRCR）远端结构域1结合发挥作用。已发现依妥珠单抗是安全的，输注反应是最常见的不良反应。然而，与其他生物制剂和免疫抑制剂相比，其优缺点尚需明确。此外，正在探索其在治疗其他免疫介导疾病方面的效用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f96/5527725/eb13ed6701dd/IJD-62-418-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f96/5527725/eb13ed6701dd/IJD-62-418-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f96/5527725/eb13ed6701dd/IJD-62-418-g001.jpg

相似文献

1
Itolizumab in Psoriasis.依托珠单抗治疗银屑病。
Indian J Dermatol. 2017 Jul-Aug;62(4):418-421. doi: 10.4103/ijd.IJD_467_16.
2
Itolizumab, a novel anti-CD6 monoclonal antibody: a safe and efficacious biologic agent for management of psoriasis.依妥珠单抗，一种新型抗CD6单克隆抗体：用于治疗银屑病的安全有效的生物制剂。
Expert Opin Biol Ther. 2017 Mar;17(3):395-402. doi: 10.1080/14712598.2017.1279601. Epub 2017 Jan 25.
3
Itolizumab - a humanized anti-CD6 monoclonal antibody with a better side effects profile for the treatment of psoriasis.依特珠单抗-一种人源化抗 CD6 单克隆抗体，具有更好的副作用特征，可用于治疗银屑病。
Clin Cosmet Investig Dermatol. 2015 Apr 17;8:215-22. doi: 10.2147/CCID.S47784. eCollection 2015.
4
Itolizumab - A New Biologic for Management of Psoriasis and Psoriatic Arthritis.依他珠单抗——一种用于治疗银屑病和银屑病关节炎的新型生物制剂。
Case Rep Dermatol. 2017 Aug 23;9(2):141-145. doi: 10.1159/000475519. eCollection 2017 May-Aug.
5
T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab.T细胞的激活和分化由一种CD6结构域1抗体——托珠单抗进行调节。
PLoS One. 2017 Jul 3;12(7):e0180088. doi: 10.1371/journal.pone.0180088. eCollection 2017.
6
Off-label Use of Itolizumab in Patients with COVID-19 ARDS: Our Clinical Experience in a Dedicated COVID Center.英夫利昔单抗在新冠病毒感染所致急性呼吸窘迫综合征患者中的超说明书用药：我们在一家专门的新冠治疗中心的临床经验
Indian J Crit Care Med. 2021 Apr;25(4):467-469. doi: 10.5005/jp-journals-10071-23787.
7
Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study.新型抗 CD6 单克隆抗体itolizumab 治疗中重度慢性斑块型银屑病的疗效和安全性：一项双盲、随机、安慰剂对照、III 期研究结果。
J Am Acad Dermatol. 2014 Sep;71(3):484-92. doi: 10.1016/j.jaad.2014.01.897. Epub 2014 Apr 2.
8
Spotlight on itolizumab in the treatment of psoriasis - current perspectives from India.聚焦依托珠单抗治疗银屑病——来自印度的当前观点
Psoriasis (Auckl). 2019 May 3;9:19-27. doi: 10.2147/PTT.S154073. eCollection 2019.
9
Therapeutic Targeting of CD6 in Autoimmune Diseases: A Review of Cuban Clinical Studies with the Antibodies IOR-T1 and Itolizumab.自身免疫性疾病中CD6的治疗靶点：古巴使用抗体IOR-T1和英夫利昔单抗的临床研究综述
Curr Drug Targets. 2016;17(6):666-77. doi: 10.2174/1389450117666160201114308.
10
Clinical Outcome of a Novel Anti-CD6 Biologic Itolizumab in Patients of Psoriasis with Comorbid Conditions.新型抗CD6生物制剂艾托珠单抗在合并症银屑病患者中的临床疗效
Dermatol Res Pract. 2016;2016:1316326. doi: 10.1155/2016/1316326. Epub 2016 Nov 2.

引用本文的文献

1
A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19.一项双臂、随机、对照、多中心、开放性标签的 2 期研究，旨在评估 Itolizumab 在 COVID-19 引起的中重度 ARDS 患者中的疗效和安全性。
Expert Opin Biol Ther. 2021 May;21(5):675-686. doi: 10.1080/14712598.2021.1905794. Epub 2021 Apr 9.
2
Asthmatic patient's preferences regarding frequency of physician consultation.哮喘患者对医生问诊频率的偏好。
Saudi Pharm J. 2021 Feb;29(2):201-205. doi: 10.1016/j.jsps.2021.01.003. Epub 2021 Jan 27.
3

本文引用的文献

1
Severe recalcitrant psoriasis treated with itolizumab, a novel anti-CD6 monoclonal antibody.用新型抗CD6单克隆抗体依妥珠单抗治疗重度顽固性银屑病。
Indian J Dermatol Venereol Leprol. 2016 Jul-Aug;82(4):459-61. doi: 10.4103/0378-6323.181466.
2
Long-term efficacy and safety of itolizumab in patients with moderate-to-severe chronic plaque psoriasis: A double-blind, randomized-withdrawal, placebo-controlled study.依妥珠单抗治疗中重度慢性斑块状银屑病患者的长期疗效和安全性：一项双盲、随机撤药、安慰剂对照研究。
J Am Acad Dermatol. 2015 Aug;73(2):331-3.e1. doi: 10.1016/j.jaad.2015.03.040.
3
Immunogenicity of biologic treatments for psoriasis: therapeutic consequences and the potential value of concomitant methotrexate.
The landscape of novel and complementary targets for immunotherapy: an analysis of gene expression in the tumor microenvironment.
免疫疗法的新型及补充靶点格局：肿瘤微环境中的基因表达分析
Oncotarget. 2019 Jul 16;10(44):4532-4545. doi: 10.18632/oncotarget.27027.
银屑病生物治疗的免疫原性：治疗后果及同时应用甲氨蝶呤的潜在价值。
Am J Clin Dermatol. 2015 Aug;16(4):285-294. doi: 10.1007/s40257-015-0131-y.
4
Itolizumab - a humanized anti-CD6 monoclonal antibody with a better side effects profile for the treatment of psoriasis.依特珠单抗-一种人源化抗 CD6 单克隆抗体，具有更好的副作用特征，可用于治疗银屑病。
Clin Cosmet Investig Dermatol. 2015 Apr 17;8:215-22. doi: 10.2147/CCID.S47784. eCollection 2015.
5
Itolizumab provides sustained remission in plaque psoriasis: a 5-year follow-up experience.依妥珠单抗可使斑块状银屑病实现持续缓解：一项5年随访经验
Clin Exp Dermatol. 2015 Mar;40(2):152-5. doi: 10.1111/ced.12509. Epub 2014 Dec 12.
6
Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study.新型抗 CD6 单克隆抗体itolizumab 治疗中重度慢性斑块型银屑病的疗效和安全性：一项双盲、随机、安慰剂对照、III 期研究结果。
J Am Acad Dermatol. 2014 Sep;71(3):484-92. doi: 10.1016/j.jaad.2014.01.897. Epub 2014 Apr 2.
7
Immunological and histological evaluation of clinical samples from psoriasis patients treated with anti-CD6 itolizumab.使用抗CD6艾托珠单抗治疗的银屑病患者临床样本的免疫学和组织学评估。
MAbs. 2014 May-Jun;6(3):783-93. doi: 10.4161/mabs.28376. Epub 2014 Mar 4.
8
A clinical exploratory study with itolizumab, an anti-CD6 monoclonal antibody, in patients with rheumatoid arthritis.一项使用抗CD6单克隆抗体艾托珠单抗治疗类风湿关节炎患者的临床探索性研究。
Results Immunol. 2012 Nov 21;2:204-11. doi: 10.1016/j.rinim.2012.11.001. eCollection 2012.
9
CD6 synergistic co-stimulation promoting proinflammatory response is modulated without interfering with the activated leucocyte cell adhesion molecule interaction.CD6 协同共刺激促进促炎反应的调节，而不干扰活化白细胞细胞黏附分子的相互作用。
Clin Exp Immunol. 2010 Oct;162(1):116-30. doi: 10.1111/j.1365-2249.2010.04235.x. Epub 2010 Aug 19.